| scholarly article | Q13442814 |
| P50 | author | Claire Bombardier | Q28322236 |
| David T Felson | Q37393431 | ||
| P2093 | author name string | Paulus H | |
| Anderson JJ | |||
| Katz LM | |||
| Boers M | |||
| Strand V | |||
| Furst D | |||
| Goldsmith C | |||
| Lightfoot R Jr | |||
| P433 | issue | 6 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 727-735 | |
| P577 | publication date | 1995-06-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | |
| P478 | volume | 38 |
| Q36702069 | Q36702069 |
| Q95359270 | Q95359270 |
| Q43280906 | 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations |
| Q26828418 | 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis |
| Q34500921 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis |
| Q57245378 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis |
| Q46815762 | 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri |
| Q38849148 | 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology |
| Q47924181 | 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology |
| Q38849144 | 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri |
| Q46885439 | 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis |
| Q36725034 | A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). |
| Q91944393 | A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis |
| Q64291316 | A Longitudinal Study of the 28 Joints of Disease Activity Score by Ultrasonographical Examination in Rheumatoid Arthritis Patients |
| Q37456300 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis |
| Q38583668 | A Note on the Validity and Reliability of Multi-Criteria Decision Analysis for the Benefit-Risk Assessment of Medicines |
| Q34533371 | A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy |
| Q47755963 | A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis |
| Q36438294 | A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans |
| Q51317650 | A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis. |
| Q58778004 | A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis |
| Q52863944 | A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. |
| Q81786169 | A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China |
| Q50132265 | A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. |
| Q42159140 | A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. |
| Q35554643 | A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. |
| Q84573128 | A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate |
| Q37601368 | A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. |
| Q36200678 | A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal |
| Q24804729 | A model of impairment and functional limitation in rheumatoid arthritis |
| Q34413341 | A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis |
| Q64088699 | A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Huangqi Guizhi Wuwutang granule in patients with rheumatoid arthritis |
| Q37133200 | A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Tong Luo Hua Shi capsule, a modernized Tibetan medicine, in patients with rheumatoid arthritis |
| Q24794291 | A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. |
| Q33659050 | A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks |
| Q84278833 | A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis |
| Q34346378 | A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis |
| Q52562279 | A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-D-mannuronic acid in rheumatoid arthritis patients. |
| Q46483294 | A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors |
| Q40498732 | A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation |
| Q33921820 | A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active [...] |
| Q37245184 | A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue |
| Q37561560 | A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. |
| Q35914971 | A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). |
| Q40372208 | A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate |
| Q35554167 | A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis |
| Q41449525 | A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis |
| Q33675468 | A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial |
| Q35810927 | A randomized trial to compare exercise treatment methods for patients after total knee replacement: protocol paper |
| Q24793114 | A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626 |
| Q87526876 | A randomized, double-blind, and placebo-controlled multicenter clinical trial of a novel cytotoxic T-lymphocyte antigen-4 fusion protein, Leining, in Chinese active rheumatoid arthritis patients with an inadequate response to methotrexate |
| Q35174234 | A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies |
| Q38236514 | A review of disease activity measures for psoriatic arthritis: what is the best approach? |
| Q53791793 | A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. |
| Q36869412 | A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index |
| Q37587005 | A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis. |
| Q37160391 | A systematic review of infliximab in the treatment of early rheumatoid arthritis |
| Q31105054 | A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes. |
| Q35069241 | A traditional Chinese medicine versus Western combination therapy in the treatment of rheumatoid arthritis: two-stage study protocol for a randomized controlled trial |
| Q62633597 | ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate |
| Q78124689 | ACR 20: clinical or statistical significance? |
| Q79288732 | Abatacept |
| Q45419013 | Abatacept (CTLA-4IG) treatment reduces the migratory capacity of monocytes in patients with rheumatoid arthritis |
| Q24240131 | Abatacept for rheumatoid arthritis |
| Q24242770 | Abatacept for rheumatoid arthritis |
| Q56891106 | Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives |
| Q48738063 | Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. |
| Q42663781 | Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis |
| Q37015967 | Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis |
| Q34449851 | Abatacept: the evidence for its place in the treatment of rheumatoid arthritis |
| Q48076353 | Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective |
| Q40134581 | Acupuncture for symptom management of rheumatoid arthritis: a pilot study |
| Q24817087 | Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score |
| Q35093636 | Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease |
| Q35953319 | Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial |
| Q34896439 | Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study |
| Q36708319 | Adalimumab for rheumatoid arthritis |
| Q24245520 | Adalimumab for treating rheumatoid arthritis |
| Q24246674 | Adalimumab for treating rheumatoid arthritis |
| Q38169508 | Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials. |
| Q34118958 | Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study |
| Q41937791 | Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial |
| Q47702978 | Additive combination of actarit and methotrexate in the treatment of refractory rheumatoid arthritis |
| Q46048883 | Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial |
| Q26852631 | Adult-onset Still's disease |
| Q35549353 | Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands |
| Q28552773 | Agreements and Discrepancies between FDA Reports and Journal Papers on Biologic Agents Approved for Rheumatoid Arthritis: A Meta-Research Project |
| Q33676083 | American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial |
| Q54573270 | American College of Rheumatology hybrid measure for assessing efficacy of treatment in patients with refractory rheumatoid arthritis: comment on the article by Genovese et al. |
| Q53150640 | American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. |
| Q35047250 | American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials |
| Q39067609 | An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology |
| Q41915136 | An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis |
| Q42663316 | An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). |
| Q46066669 | An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents |
| Q36055449 | An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists |
| Q24241707 | Anakinra for rheumatoid arthritis |
| Q24243387 | Anakinra for rheumatoid arthritis |
| Q43061720 | Anakinra in the treatment of rheumatic disease |
| Q30715455 | Analysis of trial data for infliximab and golimumab: baseline C-reactive protein level and prediction of therapeutic response in patients with psoriatic arthritis |
| Q33579417 | Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis |
| Q40845933 | Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis |
| Q43195995 | Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis |
| Q36631211 | Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review |
| Q37741879 | Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice |
| Q35552614 | Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis |
| Q45984342 | Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. |
| Q55316418 | Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. |
| Q36968787 | Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) |
| Q36942993 | Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis |
| Q36408155 | Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities |
| Q74242481 | Area under the curve for the American College of Rheumatology improvement criteria: a valid addition to existing criteria in rheumatoid arthritis? |
| Q91695792 | Arthritis sensory and motor scale: predicting functional deficits from the clinical score in collagen-induced arthritis |
| Q36486374 | Aspects of early arthritis. Traditional DMARD therapy: is it sufficient? |
| Q40471914 | Assessing the activity of rheumatoid arthritis. |
| Q51745001 | Assessment of the treat-to-target strategy in patients with refractory rheumatoid arthritis. A prospective study on efficacy and safety in a Saudi population. |
| Q34394122 | Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of t |
| Q53373730 | Association between serum thymosin β4 levels of rheumatoid arthritis patients and disease activity and response to therapy. |
| Q42639324 | Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis |
| Q34063456 | Association of physical function and physical activity in women with rheumatoid arthritis |
| Q46071397 | Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial |
| Q34897630 | Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study |
| Q28143552 | Auranofin versus placebo in rheumatoid arthritis |
| Q24800888 | Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment |
| Q24187687 | Ayurveda interventions for rheumatoid arthritis |
| Q33523412 | Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial |
| Q24235447 | Balance training (proprioceptive training) for patients with rheumatoid arthritis |
| Q24240247 | Balance training (proprioceptive training) for patients with rheumatoid arthritis |
| Q38761997 | Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis. |
| Q54123254 | Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. |
| Q94327588 | Baricitinib for rheumatoid arthritis |
| Q38840787 | Baricitinib for the treatment of rheumatoid arthritis |
| Q55251974 | Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis. |
| Q37604501 | Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study |
| Q37696609 | Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment |
| Q35012157 | Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis |
| Q37347655 | Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity |
| Q38993250 | Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. |
| Q36195284 | Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). |
| Q35807230 | Biological agents for rheumatoid arthritis: targeting both physical function and structural damage |
| Q82216428 | Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events |
| Q24240731 | Biologics for rheumatoid arthritis: an overview of Cochrane reviews |
| Q24240891 | Biologics for rheumatoid arthritis: an overview of Cochrane reviews |
| Q30234528 | Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. |
| Q30235341 | Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. |
| Q24185797 | Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis |
| Q26776432 | Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? |
| Q53434939 | Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future. |
| Q78124802 | Blindedness in clinical trials of therapies for rheumatoid arthritis: comment on the article by Bresnihan et al |
| Q57244886 | Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: Comment on the concise communication by Boers |
| Q37270792 | Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis |
| Q43800165 | Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone |
| Q24188110 | Botulinum toxin for subacute/chronic neck pain |
| Q24235339 | Botulinum toxin for subacute/chronic neck pain |
| Q24236755 | Botulinum toxin for subacute/chronic neck pain |
| Q36702456 | Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics |
| Q34098412 | Brief report: rheumatoid arthritis response criteria and patient-reported improvement in arthritis activity: is an American College of Rheumatology twenty percent response meaningful to patients? |
| Q37735544 | CCL3 and MMP-9 are induced by TL1A during death receptor 3 (TNFRSF25)-dependent osteoclast function and systemic bone loss |
| Q82332974 | CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis |
| Q47306233 | Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate |
| Q59650804 | Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFα therapy in rheumatoid arthritis? |
| Q56420736 | Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission? |
| Q46394309 | Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example |
| Q37277626 | Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis |
| Q24186209 | Celecoxib for rheumatoid arthritis |
| Q57318857 | Celecoxib for rheumatoid arthritis |
| Q35041910 | Celecoxib for rheumatoid arthritis. |
| Q52864698 | Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. |
| Q33914378 | Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain |
| Q39333743 | Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. |
| Q34495874 | Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety |
| Q36045392 | Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients |
| Q37676988 | Certolizumab pegol: a new biologic targeting rheumatoid arthritis |
| Q35553008 | Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis |
| Q52839527 | Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al. |
| Q37343947 | Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis. |
| Q24799187 | Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response |
| Q30351543 | Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. |
| Q37267600 | Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study |
| Q50010475 | Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120. |
| Q39118696 | Clinical endpoint sensitivity in rheumatoid arthritis: modeling and simulation |
| Q33809743 | Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis |
| Q35551028 | Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion |
| Q34071257 | Clinical outcome measures in rheumatoid arthritis |
| Q36098699 | Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein |
| Q34530950 | Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor |
| Q37960539 | Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis |
| Q35636558 | Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology |
| Q35249636 | Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study |
| Q51226661 | Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study. |
| Q46893265 | Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry |
| Q33791993 | Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis |
| Q35953220 | Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis |
| Q90457331 | Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study |
| Q36550842 | Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s |
| Q24658476 | Clinically important improvement thresholds for Harris Hip Score and its ability to predict revision risk after primary total hip arthroplasty |
| Q40924024 | Combination Therapy With and Without Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Trials |
| Q46642268 | Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression |
| Q39837952 | Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial |
| Q28343376 | Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components |
| Q24674942 | Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study |
| Q34276019 | Combinations of conventional disease-modifying antirheumatic drugs |
| Q41932172 | Comparable efficacy of standardized Ayurveda formulation and hydroxychloroquine sulfate (HCQS) in the treatment of rheumatoid arthritis (RA): a randomized investigator-blind controlled study |
| Q38815347 | Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points |
| Q43882915 | Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging |
| Q38424589 | Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis |
| Q92308398 | Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison |
| Q31077662 | Comparative effectiveness research with administrative health data in rheumatoid arthritis |
| Q48494568 | Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry |
| Q34124686 | Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial |
| Q41924053 | Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group |
| Q36171802 | Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort |
| Q30677867 | Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab |
| Q42955288 | Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo |
| Q36780936 | Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared? |
| Q24630541 | Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study |
| Q40502733 | Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis. |
| Q33668001 | Comprehensive analysis of treatment response phenotypes in rheumatoid arthritis for pharmacogenetic studies |
| Q46723428 | Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial |
| Q36677277 | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
| Q33954663 | Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis |
| Q44358193 | Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study. |
| Q36489884 | Content validity of the Dutch Rheumatoid Arthritis Impact of Disease (RAID) score: results of focus group discussions in established rheumatoid arthritis patients and comparison with the International Classification of Functioning, Disability and He |
| Q30822825 | Contributions of ultrasound beyond clinical data in assessing inflammatory disease activity in rheumatoid arthritis: current insights and future prospects |
| Q43760454 | Control of rheumatoid arthritis by oral tolerance |
| Q29030415 | Controlled, randomized study evaluating the effects of treating cellulite with AWT®/EPAT® |
| Q34996896 | Copper bracelets and magnetic wrist straps for rheumatoid arthritis--analgesic and anti-inflammatory effects: a randomised double-blind placebo controlled crossover trial |
| Q52004662 | Correlates of patients' global assessment of arthritis impact. A 2-year study of 216 patients with RA. |
| Q42499872 | Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab |
| Q24798428 | Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis |
| Q34958058 | Corticosteroid injections for greater trochanteric pain syndrome: a randomized controlled trial in primary care |
| Q48924619 | Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model. |
| Q41593204 | Cost-effectiveness analysis of two rituximab retreatment regimens for longstanding rheumatoid arthritis |
| Q92147073 | Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis |
| Q33717053 | Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management. |
| Q37782588 | Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review |
| Q51289760 | Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system. |
| Q34828681 | Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis |
| Q56904375 | Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion |
| Q37811971 | Criteria to define response to therapy in paediatric rheumatic diseases |
| Q37301126 | Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis |
| Q46613776 | Cross-cultural adaptation and validation of an Arabic Health Assessment Questionnaire for use in rheumatoid arthritis patients |
| Q34479140 | Current and emerging therapies for rheumatoid arthritis, with a focus on infliximab: clinical impact on joint damage and cost of care in canada |
| Q36996859 | Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review |
| Q84183105 | Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study |
| Q35552517 | Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial |
| Q35554196 | Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis |
| Q31061167 | Data-driven desirability function to measure patients' disease progression in a longitudinal study |
| Q42394345 | Decernotinib: A Next-Generation Jakinib |
| Q37191449 | Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference |
| Q43800702 | Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis F |
| Q73116677 | Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop |
| Q34811313 | Detection of inflammatory arthritis by using hyperpolarized 13C-pyruvate with MR imaging and spectroscopy |
| Q33910329 | Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis |
| Q53240881 | Developing international consensus on measures of improvement for patients with myositis. |
| Q90329265 | Developing new therapeutic approaches for rheumatoid arthritis: the continuing challenges of clinical assessments |
| Q35553458 | Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis |
| Q38601342 | Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease |
| Q37460792 | Development of a provisional core set of response measures for clinical trials of systemic sclerosis |
| Q35656228 | Development of responder definitions for fibromyalgia clinical trials |
| Q30948155 | Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy |
| Q37207010 | Developments in the clinical understanding of rheumatoid arthritis |
| Q37740969 | Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis - the TryCort study. |
| Q44980231 | Different wording of the Patient Global Visual Analogue Scale (PG-VAS) affects rheumatoid arthritis patients' scoring and the overall Disease Activity Score (DAS28): a cross-sectional study |
| Q35638652 | Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders |
| Q47422727 | Direct and Indirect Determinants of the Patient Global Assessment in Rheumatoid Arthritis: Differences by Level of Disease Activity |
| Q38099408 | Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. |
| Q50732154 | Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. |
| Q35954667 | Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis pat |
| Q57169507 | Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice |
| Q48960736 | Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. |
| Q33434163 | Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents |
| Q38698132 | Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature |
| Q56487009 | Do Patient Preferences for Core Outcome Domains for Chronic Gout Studies Support the Validity of Composite Response Criteria? |
| Q33742446 | Do outcomes reported in randomised controlled trials of joint replacement surgery fulfil the OMERACT 2.0 Filter? A review of the 2008 and 2013 literature |
| Q35553970 | Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect |
| Q37119508 | Double-blinded infliximab dose escalation in patients with rheumatoid arthritis |
| Q35933703 | Durability and rapidity of response to anakinra in patients with rheumatoid arthritis |
| Q77360241 | Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis |
| Q33585802 | Dynamic cross-talk analysis among TNF-R, TLR-4 and IL-1R signalings in TNFalpha-induced inflammatory responses |
| Q24675246 | EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides |
| Q33745949 | Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: focus on etanercept, a new biologic response modifier |
| Q92737266 | Early phase and adaptive design clinical trials in rheumatoid arthritis: a systematic review of early phase trials |
| Q36563395 | Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials |
| Q43871018 | Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomised controlled trial |
| Q53375302 | Editorial: A New Classification of Adult Autoimmune Myositis. |
| Q53760790 | Editorial: The Enduring Value of Reporting Randomized Controlled Clinical Trials in Arthritis & Rheumatology: 2016 and Beyond. |
| Q92115742 | Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial |
| Q34228353 | Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study |
| Q37465550 | Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). |
| Q24658507 | Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate |
| Q48250006 | Effect of electro-acupuncture on tumor necrosis factor-α and vascular endothelial growth factor in peripheral blood and joint synovia of patients with rheumatoid arthritis |
| Q43683228 | Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study |
| Q81230826 | Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis |
| Q35549517 | Effect of intensive exercise on patients with active rheumatoid arthritis: a randomised clinical trial |
| Q55049410 | Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. |
| Q37115728 | Effect of periodontal treatment on the clinical parameters of patients with rheumatoid arthritis: study protocol of the randomized, controlled ESPERA trial |
| Q48674125 | Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate |
| Q35555281 | Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity |
| Q35552129 | Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection |
| Q35823650 | Effective use of TNF antagonists |
| Q34027624 | Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy |
| Q46167018 | Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry |
| Q33566374 | Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions |
| Q39314826 | Effectiveness of arthroscopic synovectomy in rheumatoid arthritis |
| Q44067316 | Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis |
| Q90195194 | Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis |
| Q44123361 | Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. |
| Q54322103 | Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group stud |
| Q54493171 | Effects of glucosamine administration on patients with rheumatoid arthritis. |
| Q34152929 | Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis |
| Q46956052 | Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios |
| Q45085691 | Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis |
| Q91622660 | Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled |
| Q34533379 | Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate |
| Q40948833 | Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial |
| Q35557906 | Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study |
| Q88073084 | Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies |
| Q36930704 | Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate |
| Q41449533 | Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis |
| Q37873493 | Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
| Q58204808 | Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial |
| Q64990309 | Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials. |
| Q38200927 | Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice |
| Q37172815 | Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study |
| Q46030948 | Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. |
| Q37172820 | Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial |
| Q54268275 | Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial. |
| Q53828369 | Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial. |
| Q37382449 | Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis |
| Q43172639 | Efficacy and safety of ketoprofen patch in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study |
| Q52225534 | Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. |
| Q37081446 | Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate |
| Q92213919 | Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3) |
| Q92213914 | Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan |
| Q46467386 | Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial |
| Q35636772 | Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study |
| Q43019736 | Efficacy and safety of tacrolimus in 101 consecutive patients with rheumatoid arthritis |
| Q33659249 | Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas |
| Q40184147 | Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study |
| Q35552265 | Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study |
| Q24658506 | Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study |
| Q35020811 | Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. |
| Q50906224 | Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. |
| Q40705952 | Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). |
| Q57469182 | Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study |
| Q34056237 | Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR) |
| Q47991516 | Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy |
| Q38993297 | Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses |
| Q33389401 | Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis |
| Q36036975 | Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis |
| Q47879980 | Efficacy of golimumab for preventing large joint destruction in patients with rheumatoid arthritis as determined by the ARASHI score |
| Q52839293 | Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis. |
| Q24674877 | Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis |
| Q38125382 | Efficacy of methylprednisolone versus other pharmacologic interventions for the treatment of central post-stroke pain: a retrospective analysis |
| Q44124051 | Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study |
| Q94446131 | Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis |
| Q41026824 | Efficacy of ultrasound elastography in detecting active myositis in children: can it replace MRI? |
| Q90355990 | Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2 |
| Q92095820 | Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology |
| Q40169515 | Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials |
| Q37210207 | Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study |
| Q38993229 | Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis |
| Q58204680 | Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study |
| Q36062038 | Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis |
| Q35026464 | Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations |
| Q92737334 | Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: real-world data from a university centre registry |
| Q34546972 | Electromagnetic fields for the treatment of osteoarthritis |
| Q38543453 | Epidemiology research in rheumatology-progress and pitfalls. |
| Q36145793 | Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis |
| Q62641854 | Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment |
| Q35637985 | Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison |
| Q24202751 | Etanercept for the treatment of rheumatoid arthritis |
| Q24248004 | Etanercept for the treatment of rheumatoid arthritis |
| Q35116180 | Etanercept in psoriatic arthritis |
| Q40578875 | Etanercept in the treatment of adult patients with Still's disease |
| Q74265787 | Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial |
| Q35638615 | Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects |
| Q35551908 | Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. |
| Q37337186 | Etanercept-Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis |
| Q35938511 | Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis |
| Q33684274 | Etanercept: a review of its use in rheumatoid arthritis |
| Q34991484 | Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis |
| Q37954714 | Etanercept: efficacy and safety for approved indications |
| Q47338654 | European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib |
| Q35620336 | Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors |
| Q35555648 | Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis |
| Q35638560 | Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept |
| Q74510640 | Evaluation of a structured multidisciplinary day care program in rheumatoid arthritis. A similar effect in newly diagnosed and long-standing disease |
| Q37294493 | Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis |
| Q89996731 | Evaluation of composite responder outcomes of pain intensity and physical function in neuropathic pain clinical trials: an ACTTION individual patient data analysis |
| Q33392167 | Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data |
| Q41410246 | Evaluation of early rheumatoid arthritis disease activity and outcome |
| Q54058396 | Evaluation of filtration leucocytapheresis for use in the treatment of patients with rheumatoid arthritis. |
| Q38711889 | Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis |
| Q36414271 | Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition |
| Q36488075 | Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials |
| Q53226294 | Evaluation of the Choroid, Fovea, and Retinal Nerve Fiber Layer in Patients with Rheumatoid Arthritis. |
| Q36519316 | Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. |
| Q39032626 | Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial |
| Q38492012 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update |
| Q57173922 | Exercise for rheumatoid arthritis of the hand |
| Q24242867 | Exercise for treating fibromyalgia syndrome |
| Q24200886 | Exercise therapy for the rheumatoid hand |
| Q24186465 | Exercises for mechanical neck disorders |
| Q24201604 | Exercises for mechanical neck disorders |
| Q28389062 | Exposure-response modeling of clinical end points using latent variable indirect response models |
| Q40147073 | Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients |
| Q35555441 | Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis |
| Q46443885 | Extending the latent variable model for extra correlated longitudinal dichotomous responses. |
| Q36896228 | Extracts of Tripterygium wilfordii Hook F in the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-Analysis of Randomised Controlled Trials |
| Q41139422 | FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. |
| Q36220823 | Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis |
| Q92771511 | Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis |
| Q28081736 | Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary |
| Q44062289 | Folic acid and folinic acid supplementation during low-dose methotrexate therapy for rheumatoid arthritis: comment on the article by van Ede et al. |
| Q73202483 | Folic acid supplementation and methotrexate efficacy: comment on articles by Schiff, Emery et al, and others |
| Q41963511 | Follow up studies in rheumatoid arthritis |
| Q73065130 | Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group |
| Q34601741 | Gene expression profiles: creating new perspectives in arthritis research |
| Q35552768 | Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis |
| Q36757006 | Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study. |
| Q30717002 | Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis |
| Q24240895 | Golimumab for rheumatoid arthritis |
| Q36023494 | Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study |
| Q41517903 | Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study |
| Q34609376 | Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial |
| Q34637048 | Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160 |
| Q46585904 | Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial |
| Q34601527 | Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study |
| Q44911715 | Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function fin |
| Q37684575 | Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis |
| Q36024297 | Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry |
| Q48148396 | Greater rheumatoid arthritis joint improvement with more subjects achieving response across improvement categories using novel versus existing ultrasound methods |
| Q36610390 | Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study |
| Q37465523 | Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial |
| Q81399099 | Health-related quality of life in rheumatoid arthritis: therapeutic education plus pharmacological treatment versus pharmacological treatment only |
| Q43492890 | Health-related quality of life in young adult patients with rheumatoid arthritis in Iran: reliability and validity of the Persian translation of the PedsQL™ 4.0 Generic Core Scales Young Adult Version. |
| Q35760039 | High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis |
| Q59042851 | High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: Short-term efficacy correlates with reduction of macroscopic and histologic synovitis |
| Q37600926 | High-resolution (18)F-FDG PET/CT for assessing disease activity in rheumatoid and psoriatic arthritis: findings of a prospective pilot study. |
| Q34149748 | Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: a randomized controlled clinical trial. |
| Q41978690 | How do you know? |
| Q46011235 | IL-1beta, IL-6, and TNF gene polymorphisms do not affect the treatment outcome of rheumatoid arthritis patients with leflunomide. |
| Q51608422 | Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells. |
| Q34511936 | Immune-based therapies: a review of clinical endpoints used in trials of selected immunologic agents |
| Q40610908 | Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Prosorba Trial Investigators |
| Q35581131 | Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases |
| Q42210089 | Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO. |
| Q37236947 | Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis |
| Q39157244 | Impact of the size and number of swollen joints on serum C-reactive protein level and erythrocyte sedimentation rate in rheumatoid arthritis: a cross-sectional study in Japan |
| Q37380288 | Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study |
| Q34553844 | Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study |
| Q40339471 | Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis |
| Q31110280 | Improving the power of clinical trials of rheumatoid arthritis by using data on continuous scales when analysing response rates: an application of the augmented binary method |
| Q73070614 | In vitro migration of mononuclear cells towards synovial fluid and plasma from rheumatoid arthritis patients correlates to RANTES synovial fluid levels and to clinical pain parameters |
| Q54971191 | Incidence of total knee replacement subsequent to intra-articular injection of the anti-inflammatory compound LMWF-5A versus saline: a long-term follow-up study to a randomized controlled trial. |
| Q44564160 | Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator |
| Q48178182 | Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. |
| Q56334428 | Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial |
| Q46760849 | Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment |
| Q37427257 | Inflammatory arthritis: an overview for primary care physicians |
| Q46055310 | Inflammatory immune cell responses and Toll-like receptor expression in synovial tissues in rheumatoid arthritis patients treated with biologics or DMARDs |
| Q33885648 | Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group |
| Q34758388 | Infliximab for the treatment of rheumatoid arthritis |
| Q35636983 | Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis |
| Q35555905 | Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial |
| Q42955115 | Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience |
| Q34620291 | Infliximab in the treatment of plaque type psoriasis |
| Q35760193 | Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial |
| Q59546338 | Infliximab therapy efficacy and persistence at a Canadian academic centre despite a change in access procedure |
| Q46812628 | Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment |
| Q43263555 | Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years' drug survival |
| Q38320157 | Infliximab, methotrexate and their combination for the treatment of rheumatoid arthritis: a systematic review and meta-analysis |
| Q35632732 | Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis |
| Q33959133 | Infliximab: a review of its use in the management of rheumatoid arthritis |
| Q50327361 | Influence of corticosteroids on C-reactive protein in patients with rheumatoid arthritis. |
| Q36573901 | InforMatrix: treatment of rheumatoid arthritis using biologicals |
| Q35553767 | Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis |
| Q74023929 | Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients |
| Q90115232 | Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial |
| Q29300519 | Injectable gold for rheumatoid arthritis |
| Q40963970 | Innovative treatment approaches for rheumatoid arthritis. Issues in clinical trials of biological agents |
| Q34237578 | Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study |
| Q73165816 | Intensified-dose (4 gm/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis |
| Q36639873 | Interleukin 6: from bench to bedside |
| Q94397565 | Interleukin inhibitors for psoriatic arthritis |
| Q34343286 | Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy |
| Q34047753 | Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications |
| Q37928726 | Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: practical applications for rheumatology healthcare providers |
| Q34264322 | Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol. |
| Q24200961 | Interventions for periodontal disease in people with rheumatoid arthritis |
| Q39214412 | Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study |
| Q55224861 | Intra-articular injection of the anti-inflammatory compound LMWF-5A in adults with severe osteoarthritis: a double-blind prospective randomized controlled multi-center safety and efficacy trial. |
| Q39705167 | Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. |
| Q40340532 | Intravenous application of omega-3 fatty acids in patients with active rheumatoid arthritis. The ORA-1 trial. An open pilot study |
| Q33588504 | Is rheumatoid arthritis a disease that starts in the intestine? A pilot study comparing an elemental diet with oral prednisolone |
| Q37335856 | Issues in the design of new clinical trials for rheumatoid arthritis therapeutics |
| Q47148249 | Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1. |
| Q58759049 | Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor in |
| Q34538249 | Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perio |
| Q35646563 | Jingtong Granule: A Chinese Patent Medicine for Cervical Radiculopathy |
| Q34033218 | Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints |
| Q57142633 | Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab |
| Q74384518 | Juvenile arthritis and autoimmunity to type II collagen |
| Q36277831 | Kinase inhibitors: a new class of antirheumatic drugs |
| Q35828195 | Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide |
| Q46353544 | Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint |
| Q85811717 | Latent variable indirect response modeling of categorical endpoints representing change from baseline |
| Q46602549 | Leflunomide (Arava) is a useful DMARD in Indian (Asian) patients: a clinic-based observational study of 1-year treatment |
| Q35048594 | Leflunomide for treating rheumatoid arthritis |
| Q33826225 | Leflunomide: a review of its use in active rheumatoid arthritis |
| Q53814762 | Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. |
| Q73065103 | Listening to the patient: a practical guide to self-report questionnaires in clinical care |
| Q88019123 | Long term effectiveness of RA-1 as a monotherapy and in combination with disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis |
| Q34562870 | Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study |
| Q33725553 | Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients |
| Q47662522 | Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors. |
| Q91937115 | Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis |
| Q37321296 | Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. |
| Q47422556 | Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development |
| Q34975404 | Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis |
| Q36557712 | Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2) |
| Q35605418 | MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial |
| Q50127594 | MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial. |
| Q36915990 | Magnet therapy for the relief of pain and inflammation in rheumatoid arthritis (CAMBRA): a randomised placebo-controlled crossover trial |
| Q43800671 | Magnetic resonance imaging and miniarthroscopy of metacarpophalangeal joints: sensitive detection of morphologic changes in rheumatoid arthritis |
| Q41454181 | Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. |
| Q41454498 | Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, |
| Q36284932 | Managing early presentation of rheumatoid arthritis. Systematic overview. |
| Q24187058 | Manipulation and mobilisation for neck pain contrasted against an inactive control or another active treatment |
| Q24240371 | Manipulation or Mobilisation for Neck Pain |
| Q24194991 | Manual therapy with exercise for neck pain |
| Q37270882 | Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study |
| Q24200493 | Massage for mechanical neck disorders |
| Q50110839 | Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. |
| Q34187345 | Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study |
| Q34411088 | Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis |
| Q44773466 | Mean changes versus dichotomous definitions of improvement |
| Q79288142 | Means, responders, and meaning: Evaluation of clinical trials in osteoarthritis |
| Q34057574 | Measure of function in rheumatoid arthritis: individualised or classical scales? |
| Q24805412 | Measurement of global functional performance in patients with rheumatoid arthritis using rheumatology function tests |
| Q64921478 | Measurement of morning stiffness in rheumatoid arthritis clinical trials. |
| Q90355996 | Measurement properties of the minimal disease activity criteria for psoriatic arthritis |
| Q38019622 | Measures in rheumatoid arthritis: are we measuring too many parameters |
| Q35687818 | Measures of rheumatoid arthritis disease activity in Australian clinical practice |
| Q33234551 | Measuring disease activity for rheumatoid arthritis |
| Q36554724 | Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group repor |
| Q24247212 | Medicinal and Injection therapies for mechanical neck disorders |
| Q24188098 | Medicinal and injection therapies for mechanical neck disorders |
| Q24243952 | Medicinal and injection therapies for mechanical neck disorders |
| Q35959354 | Meridian-sinew release therapy for the treatment of refractory rheumatoid arthritis. |
| Q37718225 | Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis |
| Q33919427 | Methods for assessing responsiveness: a critical review and recommendations |
| Q55401837 | Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis. |
| Q94336562 | Methotrexate for psoriatic arthritis |
| Q33908140 | Methotrexate for rheumatoid arthritis |
| Q34424214 | Methotrexate for treating juvenile idiopathic arthritis |
| Q24194047 | Methotrexate for treating rheumatoid arthritis |
| Q24202055 | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis |
| Q38939820 | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. |
| Q26751187 | Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis |
| Q24235784 | Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis |
| Q42955695 | Methotrexate-induced lung injury in patients with rheumatoid arthritis occurs with peripheral blood lymphocyte count decrease |
| Q82416651 | Midterm clinico-radiologic findings of an open label observation study of add-on tacrolimus with biologics or non-biologic DMARDs |
| Q42581102 | Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. |
| Q89032928 | Minimal clinically important improvement response in patients with severe osteoarthritis of the knee: Short report from a survey of clinicians |
| Q90238670 | Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab |
| Q90073154 | Model-Based Comparison of Dose-Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients |
| Q33837678 | Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib |
| Q46456972 | Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency |
| Q33908219 | Moderate-term, low-dose corticosteroids for rheumatoid arthritis |
| Q38014684 | Molecular characterization of rheumatoid arthritis with magnetic resonance imaging. |
| Q55255795 | Molecular detection of inflammation in cell models using hyperpolarized 13C-pyruvate. |
| Q35911103 | Molecular targets in immune-mediated diseases: focus on rheumatoid arthritis |
| Q35216972 | Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis |
| Q36639868 | Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials |
| Q35770656 | Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study. |
| Q42955860 | Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count |
| Q42971950 | Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials |
| Q44806131 | N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis |
| Q39140290 | NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD. |
| Q26827651 | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report |
| Q35169049 | Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being |
| Q64271473 | New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib |
| Q36088346 | New therapies for rheumatoid arthritis |
| Q36849874 | New therapies for treatment of rheumatoid arthritis |
| Q84598859 | Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks? |
| Q41366996 | Non-inferiority margins employed in clinical trials in Japan |
| Q92720506 | Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology? |
| Q37356378 | Novel evidence-based systemic lupus erythematosus responder index |
| Q38211315 | Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials |
| Q38570721 | Novel treatment options for juvenile idiopathic arthritis |
| Q39371685 | Novel treatment strategies in rheumatoid arthritis. |
| Q30896344 | Number needed to treat (NNT): implication in rheumatology clinical practice |
| Q28245986 | Ocrelizumab: a step forward in the evolution of B-cell therapy |
| Q33847956 | Ocular manifestation of rheumatoid arthritis-different forms and frequency |
| Q24202719 | Ofatumumab for rheumatoid arthritis |
| Q35540009 | Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial |
| Q38993316 | Optimal dose of etanercept in the treatment of rheumatoid arthritis |
| Q40484774 | Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point |
| Q88239772 | Origins of Discordant Responses among 3 Rheumatoid Arthritis Improvement Criteria |
| Q24243689 | Orthoses for mechanical neck disorders |
| Q82732857 | Osteoporosis in psoriatic arthritis: is there any? |
| Q36333820 | Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis |
| Q35036208 | Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies |
| Q37619717 | Outcome measures in inflammatory rheumatic diseases |
| Q36140811 | Outcome measures in psoriatic arthritis |
| Q36208083 | Outcome measures in psoriatic arthritis clinical trials |
| Q57169494 | Outcome measures in rheumatoid arthritis: the OMERACT process |
| Q41446441 | Outcome measures, pooled index and quality of life instruments in rheumatoid arthritis |
| Q33782360 | PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases |
| Q39809621 | PRTX-100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double-blind, placebo-controlled, dose-escalation study |
| Q36819032 | Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study |
| Q92464711 | Pain, sleep and emotional well-being explain the lack of agreement between physician- and patient-perceived remission in early rheumatoid arthritis |
| Q24201004 | Patient education for neck pain |
| Q26852960 | Patient reported outcomes in rheumatoid arthritis clinical trials |
| Q38822369 | Patient-Reported Outcomes in Psoriatic Arthritis. |
| Q34803148 | Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial |
| Q38910063 | Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach. |
| Q35769101 | Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. |
| Q37064772 | Patients with suspected rheumatoid arthritis should be referred early to rheumatology |
| Q39020448 | Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis. |
| Q40504454 | Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate |
| Q33413162 | Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline |
| Q24243285 | Percutaneous vertebroplasty for osteoporotic vertebral compression fracture |
| Q31038425 | Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors |
| Q41065857 | Periodontal pathogens participate in synovitis in patients with rheumatoid arthritis in clinical remission: a retrospective case-control study |
| Q26771652 | Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability |
| Q60935710 | Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment |
| Q40191979 | Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis |
| Q38084444 | Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine |
| Q88790397 | Pharmacogenomics in the treatment of rheumatoid arthritis: clinical implication and perspective |
| Q89689953 | Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm St |
| Q38097969 | Pharmacokinetic consideration of synthetic DMARDs in rheumatoid arthritis |
| Q42635758 | Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients |
| Q26830621 | Pharmacokinetic/pharmacodynamic modeling in inflammation |
| Q41758222 | Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis |
| Q37030677 | Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis |
| Q59137786 | Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate |
| Q45982095 | Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. |
| Q47918450 | Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis |
| Q34477442 | Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. |
| Q34172853 | Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs |
| Q94322276 | Phosphodiesterase 4 inhibitors for psoriatic arthritis |
| Q37249585 | Physician-delivered injection therapies for mechanical neck disorders: a systematic review update (non-oral, non-intravenous pharmacological interventions for neck pain) |
| Q45034864 | Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome |
| Q36821030 | Plasma exchange for rheumatoid arthritis |
| Q51422302 | Plasmapheresis therapy in combination with TNF-α inhibitor and DMARDs: A multitarget method for the treatment of rheumatoid arthritis. |
| Q60622667 | Polyarthrite rhumatoïde associée à un trait bêta-thalassémique : aspect clinique, sérologique et immunogénétique |
| Q45792506 | Positive synovial vascularity in patients with low disease activity indicates smouldering inflammation leading to joint damage in rheumatoid arthritis: time-integrated joint inflammation estimated by synovial vascularity in each finger joint |
| Q93037024 | Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial |
| Q42956746 | Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate |
| Q93384223 | Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study |
| Q37502434 | Predicting and verifying outcome of Tripterygium wilfordii Hook F. based therapy in rheumatoid arthritis: from open to double-blinded randomized trial |
| Q35899269 | Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year |
| Q58412739 | Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis: Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome-Wide DNA Microarray |
| Q57471049 | Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data |
| Q35552077 | Predictors of patient relevant outcome after total hip replacement for osteoarthritis: a prospective study. |
| Q87339962 | Predictors of response to TNF-α antagonist therapy in Chinese rheumatoid arthritis |
| Q24675216 | Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7 |
| Q58204736 | Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study |
| Q34767403 | Prevention or retardation of joint damage in rheumatoid arthritis: issues of definition, evaluation and interpretation of plain radiographs |
| Q36243974 | Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects |
| Q38251801 | Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives |
| Q24675003 | Psoriasis: epidemiology, clinical features, and quality of life |
| Q35579462 | Psoriatic arthritis assessment tools in clinical trials |
| Q44557662 | Psoriatic arthritis. Treatment outcome parameters |
| Q24813979 | Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment |
| Q35902691 | Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. |
| Q40527567 | Pulmonary abscess due to leflunomide use in rheumatoid arthritis: a case report |
| Q35780344 | Pursuit of optimal outcomes in rheumatoid arthritis |
| Q90725448 | Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines |
| Q40401339 | Quality of life and costs for different treatment strategies for rheumatoid arthritis |
| Q45850333 | Quality of life evaluated by Short Form-8 in patients with rheumatoid arthritis who were receiving infusion of infliximab |
| Q35213445 | Quality of life in patients with rheumatoid arthritis : which drugs might make a difference? |
| Q37269344 | Quality-of-life assessment in rheumatoid arthritis |
| Q46222268 | Quantification of (R)-[11C]PK11195 binding in rheumatoid arthritis. |
| Q35198211 | Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care |
| Q37786625 | RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis |
| Q33870130 | RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural |
| Q35159896 | RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies |
| Q35637808 | Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis |
| Q34607591 | Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placeb |
| Q53085402 | Radiographic prognosis of finger joint damage predicted by early alteration in synovial vascularity in patients with rheumatoid arthritis: Potential utility of power doppler sonography in clinical practice. |
| Q35759974 | Radiological damage in patients with rheumatoid arthritis on sustained remission |
| Q73573994 | Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis |
| Q35098842 | Randomised double-blind trial of combination antibiotic therapy in rheumatoid arthritis |
| Q44955341 | Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. |
| Q35177630 | Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy |
| Q44750988 | Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis |
| Q35804435 | Rapid Anti-Inflammatory Effects of Gonadotropin-Releasing Hormone Antagonism in Rheumatoid Arthritis Patients with High Gonadotropin Levels in the AGRA Trial |
| Q47262616 | Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate |
| Q53086414 | Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis. |
| Q93148204 | Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis |
| Q37358239 | Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis |
| Q33847017 | Recent advances in the treatment of rheumatoid arthritis |
| Q35631931 | Recombinant human interleukin receptor antagonist influences serum chemokines in patients with rheumatoid arthritis |
| Q61946755 | Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis |
| Q45929457 | Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. |
| Q36819289 | Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration |
| Q44447375 | Reexamination of the assessment criteria for rheumatoid arthritis disease activity based on comparison of the Disease Activity Score 28 with other simpler assessment methods |
| Q41184418 | Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis |
| Q46486846 | Relative contributions of the components of the American College of Rheumatology 20% criteria for improvement to responder status in patients with early seropositive rheumatoid arthritis |
| Q40701967 | Reliability and Validity of the Psoriasis Symptom Inventory in Patients With Psoriatic Arthritis |
| Q87858469 | Remission criteria and activity indices in psoriatic arthritis |
| Q46605974 | Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). |
| Q33260342 | Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies |
| Q48198050 | Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. |
| Q36461259 | Representation by standard terminologies of health status concepts contained in two health status assessment instruments used in rheumatic disease management. |
| Q36580468 | Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus |
| Q74384489 | Response criteria and criteria for clinically important improvement: separate and equal? |
| Q35555937 | Response criteria for rheumatoid arthritis in clinical practice: how useful are they? |
| Q50323773 | Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. |
| Q27692640 | Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system |
| Q43052844 | Responsiveness of the core set, response criteria, and utilities in early rheumatoid arthritis |
| Q35555131 | Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept |
| Q24800647 | Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis |
| Q35555747 | Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis |
| Q74541001 | Rheumatoid arthritis |
| Q87726283 | Rheumatoid arthritis |
| Q57349151 | Rheumatoid arthritis |
| Q37988317 | Rheumatoid arthritis and the era of biologic therapy |
| Q47862920 | Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile. |
| Q30244019 | Rheumatoid arthritis. |
| Q33400413 | Rheumatoid arthritis. Target outcome for treatment |
| Q38182471 | Rheumatoid arthritis: a case for personalized health care? |
| Q36160669 | Rheumatoid arthritis: an overview of new and emerging therapies |
| Q35085103 | Rheumatoid arthritis: proposal for the use of anti-microbial therapy in early cases |
| Q53413570 | Rheumatology, geriatrics, and a way forward. |
| Q36760300 | Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis |
| Q38234629 | Rituximab and tocilizumab for the treatment of rheumatoid arthritis |
| Q24186568 | Rituximab for rheumatoid arthritis |
| Q24242554 | Rituximab for rheumatoid arthritis |
| Q38233120 | Rituximab for rheumatoid arthrits treatment: a systematic review. |
| Q36297074 | Rituximab treatment of refractory rheumatoid arthritis |
| Q36675413 | Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis |
| Q24244836 | Rofecoxib for rheumatoid arthritis |
| Q38910201 | Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis |
| Q40095048 | Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study |
| Q35026454 | Safety and clinical efficacy of golimumab in the treatment of arthritides |
| Q37691205 | Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study |
| Q39430200 | Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. |
| Q37326017 | Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial |
| Q35048395 | Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate |
| Q34595156 | Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept |
| Q35194346 | Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis |
| Q90570827 | Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2 |
| Q38753455 | Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis |
| Q80363787 | Safety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis : a six-month randomised study |
| Q56957641 | Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial |
| Q42166609 | Safety of long-term tacrolimus therapy for rheumatoid arthritis: an open-label, uncontrolled study in non-elderly patients |
| Q38374478 | Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. |
| Q37690646 | Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials |
| Q47253208 | Sample size considerations for superiority trials in systemic lupus erythematosus (SLE). |
| Q34465354 | Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study |
| Q39176539 | Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors |
| Q61772924 | Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| Q34092311 | Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial |
| Q36040052 | Science of assessment |
| Q65001629 | Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis. |
| Q54978927 | Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. |
| Q48219239 | Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study. |
| Q57169747 | Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial |
| Q90502051 | Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5 |
| Q38989105 | Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q33651424 | Selective cyclooxygenase-2 inhibitors |
| Q51773490 | Semi-quantitative analysis of rheumatoid finger joint synovitis using power Doppler ultrasonography: when to perform follow-up study after treatment consisting mainly of antitumor necrosis factor alpha agent. |
| Q37324622 | Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials |
| Q33424033 | Sex differences in rheumatoid arthritis: more than meets the eye.. |
| Q40374825 | Short-Term Efficacy Reliably Predicts Long-Term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-Based Meta-Analysis |
| Q51752628 | Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use : open-label, prospective study. |
| Q33576876 | Silent progression in patients with rheumatoid arthritis: is DAS28 remission an insufficient goal in RA? Results from the German Remission-plus cohort |
| Q35760130 | Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol |
| Q34092469 | Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy |
| Q43685328 | Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine |
| Q44585210 | Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis |
| Q34613907 | Spondyloarthritides: evolving therapies |
| Q24727581 | Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop |
| Q43947279 | Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis |
| Q35590496 | Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. |
| Q24187565 | Subcutaneous or intramuscular methotrexate for rheumatoid arthritis |
| Q34770459 | Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis |
| Q33908146 | Sulfasalazine for rheumatoid arthritis |
| Q34498487 | Supplemental treatment of rheumatoid arthritis with natural milk antibodies against enteromicrobes and their toxins: results of an open-labelled pilot study |
| Q42675432 | Sustained Clinical Response in Psoriatic Arthritis Patients Treated with Anti-TNF Agents: A 5-year Open-Label Observational Cohort Study |
| Q49218023 | Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. |
| Q33336433 | Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes |
| Q50034734 | Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: 52-Week Phase 3 Randomized Study Results. |
| Q30612910 | Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study |
| Q60919476 | Switching of biological therapies in Brazilian patients with rheumatoid arthritis |
| Q47662613 | Symptom combinations assessed in traditional Chinese medicine and its predictive role in ACR20 efficacy response in rheumatoid arthritis |
| Q64065269 | Synovial Tissue: Turning the Page to Precision Medicine in Arthritis |
| Q35637474 | Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis |
| Q39904758 | Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade. |
| Q33240856 | Systematic review of measures and their concepts used in published studies focusing on the treatment of acute inflammatory arthritis |
| Q36294542 | Systematic review of the methodological quality of controlled trials evaluating Chinese herbal medicine in patients with rheumatoid arthritis |
| Q33400381 | Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor |
| Q36484155 | Systemic sclerosis: hypothesis-driven treatment strategies |
| Q58998545 | T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4ig but is successfully treated by interleukin-17 neutralization |
| Q34240744 | TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept |
| Q24240905 | TNF-alpha inhibitors for psoriatic arthritis |
| Q43481756 | Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial |
| Q46036804 | Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. |
| Q36349618 | Tacrolimus in rheumatoid arthritis |
| Q44616888 | Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study |
| Q90278089 | Tai Chi for rheumatoid arthritis |
| Q57476237 | Tailored, Therapist-Guided Internet-Based Cognitive Behavioral Therapy Compared to Care as Usual for Patients With Rheumatoid Arthritis: Economic Evaluation of a Randomized Controlled Trial |
| Q37303223 | Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature |
| Q77838669 | Targeting interleukin-1 in the treatment of rheumatoid arthritis |
| Q90365238 | Targeting p19 in psoriatic arthritis: more than just another therapeutic approach? |
| Q37690095 | The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing. |
| Q36758822 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q40002833 | The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis |
| Q37137011 | The Effect of Omega-3 Fatty Acids in Patients With Active Rheumatoid Arthritis Receiving DMARDs Therapy: Double-Blind Randomized Controlled Trial. |
| Q38393840 | The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis |
| Q33916770 | The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes |
| Q42675446 | The Hawthorne Effect, Sponsored Trials, and the Overestimation of Treatment Effectiveness |
| Q34242363 | The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis |
| Q36915684 | The Paediatric Rheumatology International Trials Organization (PRINTO). |
| Q57538743 | The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the Treatment of Immune-Related Diseases: A Systematic Review |
| Q36143168 | The Value of Median Nerve Sonography as a Predictor for Short- and Long-Term Clinical Outcomes in Patients with Carpal Tunnel Syndrome: A Prospective Long-Term Follow-Up Study |
| Q30914777 | The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials |
| Q48265755 | The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. |
| Q89850254 | The critical need for accurately defining digital ulcers in scleroderma |
| Q33735395 | The cyclooxygenase-2 inhibitors: safety and effectiveness |
| Q34736462 | The disablement process in rheumatoid arthritis |
| Q61946760 | The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs |
| Q45939299 | The effect of 677C>T and 1298A>C MTHFR polymorphisms on sulfasalazine treatment outcome in rheumatoid arthritis. |
| Q35157466 | The effect of OPC Factor on energy levels in healthy adults ages 45-65: a phase IIb randomized controlled trial |
| Q33586991 | The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study |
| Q46126666 | The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide |
| Q51463578 | The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. |
| Q44937970 | The effect of the Arthritis Self-Management Program on outcome in African Americans with rheumatoid arthritis served by a public hospital. |
| Q34858352 | The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis |
| Q34626882 | The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy |
| Q47620622 | The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab |
| Q44470594 | The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study |
| Q37754083 | The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials |
| Q40772658 | The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, d |
| Q57213110 | The efficacy and safety of the herbal medicine geonchildan for patients with active rheumatoid arthritis: study protocol for a randomized, double-blind, placebo-controlled, parallel pilot trial |
| Q64256884 | The efficacy of the traditional Chinese medicine Jia Wei Niu Bang Zi granule combined with methotrexate in treating active rheumatoid arthritis: A multicenter, randomized, double-blinded controlled clinical trial |
| Q55000909 | The efficacy of the traditional Chinese medicine Juanbi pill combined with methotrexate in active rheumatoid arthritis: study protocol for a randomized controlled trial. |
| Q47298646 | The extraarticular symptoms influence ACR response in the treatment of rheumatoid arthritis with biomedicine: a single-blind, randomized, controlled, multicenter trial in 194 patients |
| Q28751012 | The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis |
| Q51480854 | The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries. |
| Q33923245 | The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study |
| Q47770683 | The new use of an ancient remedy: a double-blinded randomized study on the treatment of rheumatoid arthritis |
| Q33311301 | The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review |
| Q40204659 | The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1 |
| Q43988467 | The prevalence and impact of managed care for persons with rheumatoid arthritis in 1994 and 1999. |
| Q53816779 | The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). |
| Q73194067 | The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group |
| Q35636836 | The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population |
| Q26765122 | The specialist physician's approach to rheumatoid arthritis in South Africa |
| Q39021621 | The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases |
| Q35859217 | The treatment of rheumatoid arthritis |
| Q35688168 | The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview |
| Q36916918 | The use of TNF-alpha blocking agents in rheumatoid arthritis: an update |
| Q30576366 | The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis |
| Q37633537 | Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists |
| Q33976382 | Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial |
| Q35636828 | Thermal signature analysis as a novel method for evaluating inflammatory arthritis activity. |
| Q33316236 | Three-dimensional and thermal surface imaging produces reliable measures of joint shape and temperature: a potential tool for quantifying arthritis |
| Q42667803 | Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study |
| Q24234126 | Tocilizumab for rheumatoid arthritis |
| Q24239949 | Tocilizumab for rheumatoid arthritis |
| Q36515498 | Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy |
| Q37682799 | Tocilizumab in the treatment of rheumatoid arthritis and beyond |
| Q44165611 | Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial |
| Q37310678 | Tocilizumab: an interleukin-6 receptor inhibitor for the treatment of rheumatoid arthritis |
| Q45842857 | Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial |
| Q88076637 | Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal |
| Q24198120 | Tofacitinib for rheumatoid arthritis |
| Q36513512 | Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study |
| Q58204744 | Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study |
| Q37608920 | Tools for monitoring spondyloarthritis in clinical practice |
| Q28077994 | Total glucosides of paeony for rheumatoid arthritis: a protocol for a systematic review |
| Q47650717 | Traditional Chinese medicine versus western medicine as used in China in the management of rheumatoid arthritis: a randomized, single-blind, 24-week study |
| Q80089102 | Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy |
| Q24248705 | Transcutaneous electrical nerve stimulation (TENS) for the treatment of rheumatoid arthritis in the hand |
| Q52580071 | Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. |
| Q38690324 | Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force |
| Q38476881 | Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force |
| Q34043097 | Treatment of adult-onset Still's disease: a review |
| Q36793241 | Treatment of osteoarthritis with anakinra |
| Q33659004 | Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor |
| Q38204241 | Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety |
| Q56060521 | Treatment of rheumatoid arthritis |
| Q37688075 | Treatment of rheumatoid arthritis with marine and botanical oils: an 18-month, randomized, and double-blind trial |
| Q41917264 | Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial |
| Q83980148 | Treatment of rheumatoid arthritis with ornidazole: a randomized, double-blind, placebo-controlled study |
| Q37607063 | Treatment of rheumatoid arthritis: state of the art 2009. |
| Q33946522 | Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab |
| Q50553120 | Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. |
| Q30885007 | Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense |
| Q33328963 | Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety |
| Q37008829 | Tumor necrosis factor as a therapeutic target of rheumatologic disease |
| Q34181975 | Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis |
| Q47376889 | Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis |
| Q36633112 | Ultrasound of metacarpophalangeal joints is a sensitive and reliable endpoint for drug therapies in rheumatoid arthritis: results of a randomized, two-center placebo-controlled study. |
| Q36345857 | Understanding the molecular mechanism of interventions in treating rheumatoid arthritis patients with corresponding traditional chinese medicine patterns based on bioinformatics approach. |
| Q92302942 | Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study |
| Q36869567 | Update on abatacept: a selective costimulation modulator for rheumatoid arthritis |
| Q40081220 | Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis |
| Q35662575 | Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis |
| Q37572857 | Use of Bayesian multivariate meta-analysis to estimate the HAQ for mapping onto the EQ-5D questionnaire in rheumatoid arthritis. |
| Q92193157 | Use of a "critical difference" statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritis |
| Q33854097 | Use of anatomic measurement to guide injection of botulinum toxin for the management of chronic lateral epicondylitis: a randomized controlled trial |
| Q36588861 | Use of biologics in rheumatoid arthritis: where are we going? |
| Q73348127 | Using a Serial Marker to Predict a Repeated Measures Outcome in a Cohort Study |
| Q90461853 | Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis |
| Q34154247 | Ustekinumab for the treatment of psoriatic arthritis: an update |
| Q51821980 | Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. |
| Q40949103 | VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis |
| Q36980842 | Vaccination with endosomal unknown epitopes produces therapeutic response in rheumatoid arthritis patients and modulates adjuvant arthritis of rats. |
| Q26827173 | Vagus nerve stimulation: a new bioelectronics approach to treat rheumatoid arthritis? |
| Q35174224 | Valdecoxib: a review |
| Q53642494 | Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure. |
| Q36428250 | Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity |
| Q33915344 | Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials |
| Q63101754 | Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e |
| Q34607687 | Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes |
| Q38734238 | WITHDRAWN: Celecoxib for rheumatoid arthritis. |
| Q44053035 | Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study |
| Q60910366 | Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study |
| Q74510644 | Weighting for joint surface area improves the information provided by a reduced 28-joint articular index of swollen joints |
| Q39390356 | What decline in pain intensity is meaningful to patients with acute pain? |
| Q36469884 | When Patients Write the Guidelines: Patient Panel Recommendations for the Treatment of Rheumatoid Arthritis |
| Q24673434 | When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? |
| Q81329841 | [Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)] |
| Q82638877 | [Clinical outcome measures in hand- and finger joint osteoarthritis from the patient perspective] |
| Q44679527 | [Drug therapy of rheumatoid arthritis]. |
| Q81772569 | [Four-year observation of etanercept therapy for rheumatoid arthritis in a single German center] |
| Q52849897 | [Glucocorticoids]. |
| Q84600236 | [How do we evaluate an inadequate response in a patient with rheumaoid arthritis in the clinical praxis P?] |
| Q81288165 | [Modern antirheumatic pharmacotherapy. Low molecular weight substances vs. biologicals] |
| Q82663598 | [Outcome parameters for use in psoriatic arthritis] |
| Q74042917 | [Systematic review of clinical trials on the treatment of rheumatoid arthritis with tumour necrosis factor alpha inhibitors] |
| Q89495765 | miR-155 promotes fibroblast-like synoviocyte proliferation and inflammatory cytokine secretion in rheumatoid arthritis by targeting FOXO3a |
| Q60693134 | Élaboration d’un questionnaire pour évaluer le handicap dans la polyarthrite rhumatoïde : étude préliminaire |
Search more.